Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Deering

Clinical Cardiac Electrophysiology Atlanta, GA Medical Doctor

NPI 1932104239 CMS profile 132361

275 Collier Rd Nw, Ste 500, Atlanta, GA 30309

Open in the dashboard

General payments

$236,700

250 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Deering of Atlanta, GA is reported in the CMS Open Payments database as having received $236,700 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,783 41
2024 General $21,611 56
2023 General $36,344 46
2022 General $49,255 30
2021 General $105,496 31
2020 General $14,414 16
2019 General $795 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Deering
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Thomas Deering were reported at $8,783. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Thomas Deering Clinical Cardiac Electrophysiology median Middle half National median
2019 $795 $2,361 $585–$8,260 $163
2020 $14,414 $993 $247–$4,351 $114
2021 $105,496 $1,185 $326–$4,739 $132
2022 $49,255 $2,073 $554–$6,789 $149
2023 $36,344 $2,568 $759–$8,159 $160
2024 $21,611 $2,557 $703–$7,403 $164
2025 $8,783 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $148,408 34 payments
  2. Sanofi-Aventis U.S. LLC $24,110 12 payments
  3. CVRx, Inc. $21,527 11 payments
  4. Boston Scientific Corporation $20,863 49 payments
  5. AltaThera Pharmaceuticals LLC $7,508 3 payments
  6. Medtronic, Inc. $6,544 22 payments
  7. Preventice Services, LLC $3,433 3 payments
  8. Pfizer Inc. $2,234 17 payments
  9. Novartis Pharmaceuticals Corporation $587 30 payments
  10. E.R. Squibb & Sons, L.L.C. $333 23 payments
  11. Other $1,153 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $213,735 40 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,617 5 payments
  3. Food and Beverage $7,431 183 payments
  4. Travel and Lodging $5,265 19 payments
  5. Honoraria $1,500 1 payment
  6. Grant $147 1 payment
  7. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. EP-4 $68,719 11 payments
  2. FlexAbility Ablation Catheter $43,350 4 payments
  3. EP-4 Cardiac Stimulator $32,725 6 payments
  4. Barostim Neo System $21,527 11 payments
  5. MULTAQ Cardiology/Vascular Diseases $18,957 5 payments
  6. General - Therapies $7,686 8 payments
  7. Sotalol Hydrochloride $7,508 3 payments
  8. MULTAQ Cardiology/Vascular Diseases $5,137 6 payments
  9. ELIQUIS $1,960 13 payments
  10. BG Mini Plus $1,508 2 payments
  11. Other $7,819 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

2,417

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,163,343

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

53%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 785 $791,218
Xarelto Rivaroxaban Brand 268 $303,105
Dofetilide Generic 193 $26,745
Multaq Dronedarone Hcl Brand 13 $20,654
Flecainide Acetate Generic 157 $7,522
Metoprolol Succinate Generic 238 $2,987
Sotalol Sotalol Hcl Brand 113 $2,588
Metoprolol Tartrate Generic 302 $1,854
Propafenone Hcl Generic 23 $1,354
Amiodarone Hcl Generic 77 $1,315

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$276,920

Medicare's payments for the services billed

Medicare patients

3,996

Average age 76

Services billed

10,252

1,800 women, 2,196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Ischemic heart disease 58%
Arthritis 48%
Heart failure 47%
Chronic kidney disease 42%
Diabetes 36%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $6,008
$6,008 113 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $68
$68 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $68
$68 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $54
$54 268 —
ELIQUIS
  • PFIZER INC. $29
  • E.R. Squibb & Sons, L.L.C. $23
$52 785 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record